Web6 jan. 2024 · Cutaneous T-cell lymphoma (CTCL) are a rare group of cancers that develop in the skin from T cells (a type of white blood cell). Mogamulizumab is a promising treatment for CTCL, but its most common adverse effect is a drug rash named mogamulizumab-associated rash (MAR). MAR remains poorly described, and it is difficult to tell apart … Web26 jan. 2024 · The clinical recognition and pathological confirmation of mogamulizumab-associated rash (MAR) are important to enable differentiation from cutaneous T-cell lymphoma (CTCL) progression. 6, 7 Here, we report a retrospective case series of patients seen at our centres since 2013, who had granulomatous rash mimicking MF on …
Mogamulizumab: a new tool for management of cutaneous T-cell …
Web24 sep. 2024 · We report that mogamulizumab induced skin rashes in 32% of 44 CTCL patients. These rashes were associated with long-term CTCL remission, even in the absence of specific CTCL treatment. CTCL... WebMogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma Br J Dermatol. 2024 Jan;186(1):15-16.doi: … hash brown cups with egg
Paper: Mogamulizumab-Associated Rash (MAR) Correlates with …
Web17 feb. 2024 · Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther 2024; 12: 1085–94. Article CAS Google Scholar Wang JY, Hirotsu KE, Neal TM, et al. Histopathologic characterization of mogamulizumab-associated rash. Am J Surg Pathol 2024; 44: 1666–76. WebMogamulizumab was held in 40 pts with drug rash. Of the pts who permanently discontinued mogamulizumab due to rash, 16 of 38 pts (42%) remain off systemic therapy at last follow up with ongoing response; median time off of systemic therapy for these pts was 7.8 mo (IQR: 6.1, 16.5). Web24 sep. 2024 · Mogamulizumab associated rash have been described recently in MF/SS patients: [22][23][24][25] [26] [27] they are clinically heterogeneous, and currently, four … hash brown cups with egg and sausage